

BESPONSA (inotuzumab ozogamicin)

Pre - PA Allowance

None

Prior-Approval Requirements

Age 1 year of age or older

Diagnosis

Patient must have the following

Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL)

AND ALL of the following:

- Age 18+ only: if Philadelphia chromosome-positive (Ph+), patient must have failed treatment with at least ONE tyrosine kinase inhibitor and standard chemotherapy
- Prescriber agrees to obtain ALT, AST, total bilirubin, and alkaline phosphatase prior to and following each dose of Besponsa
- 3. Prescriber agrees to monitor for signs and symptoms of hepatic veno-occlusive disease during treatment of Besponsa
- 4. Prescriber agrees **NOT** to add HSCT conditioning regimens containing alkylating agents

Prior - Approval Limits

Duration 3 months

Prior - Approval Renewal Requirements

Age 1 year of age or older

Diagnosis

Patient must have the following:

Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL)



BESPONSA (inotuzumab ozogamicin)

AND ALL of the following:

- 1. NO disease progression or unacceptable toxicities
- 2. Prescriber agrees to obtain ALT, AST, total bilirubin, and alkaline phosphatase prior to and following each dose of Besponsa
- 3. Prescriber agrees to monitor for signs and symptoms of hepatic veno-occlusive disease during treatment of Besponsa
- 4. Prescriber agrees **NOT** to add HSCT conditioning regimens containing alkylating agents

Prior - Approval Renewal Limits

Duration 6 months